Application for Regulatory Approvals, Conferences and Presentations, and …PR Newswire (press release)According to Gilead, the data submitted for the NDA support the use of idelalisib for patients with iNHL that is refractory (non-responsive) to ritux…
Application for Regulatory Approvals, Conferences and Presentations, and …MarketWatch (press release)According to Gilead, the data submitted for the NDA support the use of idelalisib for patients with iNHL that is refractory (non-responsive) to ritux…
Shark antibodies could provide key to targeting breast cancerBusiness StandardAccording to a release by the Aberdeen University, the study will investigate if shark IgNAR antibodies can be used to stop these two molecules from working and sending this …
2 Minute MedicineAnti-HLA antibodies predict worse kidney-allograft survival2 Minute MedicineStudy Rundown: This study demonstrated that donor-specific anti-HLA antibodies were heterogeneous and that their ability to bind complement significantly impac…
T. gondii antibodies implicated in maniamedwireNewsThey found that immunoglobulin (Ig)M antibodies to the protozoan were significantly elevated in individuals hospitalized with mania, but not in mentally healthy individuals or individuals with other ps…
2 Minute MedicineAntibodies Predict Kidney Graft LossMedPage TodayFive-year survival of the transplanted kidney was only 54% in patients with complement-binding, donor-specific anti-HLA antibodies, compared with 93% for those with noncomplement binding…
Boxed Warning of HBV Risk Added to Rituxan, ArezerraMedPage TodayThe FDA announced today that rituximab (Rituxan) and ofatumumab (Arzerra) will now carry a boxed warning of the risk for immunosuppression-related reactivation of hepatitis B virus (HBV)….
Hepatitis B Reactivation Prompts New Warnings for Arzerra, RituxanMonthly Prescribing ReferenceThe FDA has approved changes to the prescribing information for Arzerra (ofatumumab; GlaxoSmithKline) and Rituxan (rituximab; Genentech) to add a new warning…
|
Inovio’s DNA Tech Generates HIV Monoclonal Antibodies
Drug Discovery & Development Inovio Pharmaceuticals’ DNA plasmid technology is capable of generating therapeutic monoclonal antibodies, according to a new study published in Human Vaccines and Immunotherapeutics. In this study in mice, a prototype monoclonal antibody construct … Inovio Pharmaceuticals Inc (INO): Inovio talks monoclonal antibodies, DNA …Seeking Alpha Biotech Volume Movers: Inovio Pharmaceuticals Inc (NYSEMKT:INO), Geron …Market News Call Did Inovio Pharmaceuticals Inc (NYSEMKT:INO) find a cure for HIV?GSPInsider |
Entia Biosciences Collaborates to Develop Proprietary AntibodiesTheOTCInvestor.comEntia Biosciences (OTCQB: ERGO), a food science biotechnology company and emerging leader in the field of nutrigenomics, has built a valuable portfolio of patents coverin…